

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/B56646067C7EN.html>

Date: October 2018

Pages: 69

Price: US\$ 3,500.00 (Single User License)

ID: B56646067C7EN

Abstracts

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2018

SUMMARY

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Beta-secretase 1 (BACE1) is an enzyme that in humans is encoded by the BACE1 gene. It is responsible for the proteolytic processing of the amyloid precursor protein (APP). It cleaves at the N-terminus of the A-beta peptide sequence of APP. This leads to the generation and extracellular release of beta-cleaved soluble APP and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase.

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) pipeline Target constitutes close to 18 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 7 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 1 molecules,

respectively. Report covers products from therapy areas Central Nervous System which include indications Alzheimer's Disease, Dementia Associated With Alzheimer's Disease and Mild Cognitive Impairment.

The latest report Beta Secretase 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)

The report reviews Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics and enlists all their major and minor projects

The report assesses Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Overview

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Companies Involved in Therapeutics Development

Allgenesis Biotherapeutics Inc

Amgen Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Denali Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

H. Lundbeck AS

Novartis AG

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Drug Profiles

AG-12896 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVCRI-104P3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Inhibit BACE1 and MAPT for Alzheimer's Disease -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNP-520 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

donanemab + LY-3202626 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elenbecestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LuAF-66432 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3202626 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Activate miR-188-3p for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BACE 1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE1 for Alzheimer Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Dormant Products

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Discontinued Products

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving

Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Product Development Milestones

Featured News & Press Releases

Jul 25, 2018: Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018

Jul 19, 2018: Eisai presents phase II clinical study results of elenbecestat at (AAIC) 2018

Jun 05, 2018: Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer's Disease At 18-Months

Feb 05, 2018: Compound Designed to Fight Alzheimer's Disease Shows Promise in the Lab

Oct 31, 2017: Eisai To Present Latest Data On Elenbecestat At 10th Clinical Trials On Alzheimer's Disease

Jul 17, 2017: Eisai Presents 3 Posters On Elenbecestat at the 2017 Alzheimers Association International Conference

Mar 29, 2017: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor Elenbecestat In Early Alzheimer's Disease In Japan

Dec 12, 2016: Eisai Presents Latest Data On Bace Inhibitor Elenbecestat (E2609) At 9Th Clinical Trials On Alzheimer's Disease

Nov 18, 2016: U.S. FDA Grants Fast Track Designation For The Development Of Eisai's Bace Inhibitor E2609 For Early Alzheimer'S Disease

Oct 31, 2016: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor E2609 In Early Alzheimer's Disease

Aug 09, 2016: U.S. FDA Confirms Sufficient Data to Advance Investigational Bace Inhibitor E2609 for Treatment of Early Alzheimer's Disease to Phase III

Apr 24, 2013: GE Healthcare And Eisai To Partner On Alzheimer's Disease Research

Jul 19, 2012: Eisai Presents First Clinical Data For BACE Inhibitor E2609 At AAIC 2012

Jul 13, 2012: Eisai To Present First Clinical Data For Bace Inhibitor E2609 At Alzheimer's Association International Conference 2012

Jun 08, 2012: Takeda Announces Transfer Of TAK-070 To National University Corporation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Allgenesi Biotherapeutics Inc, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Denali Therapeutics Inc, H2 2018
Pipeline by Eisai Co Ltd, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by H. Lundbeck AS, H2 2018
Pipeline by Novartis AG, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Allgenesis Biotherapeutics Inc

Amgen Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Denali Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

H. Lundbeck AS

Novartis AG

I would like to order

Product name: Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/B56646067C7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B56646067C7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970